Discussion on the Clinical Pathological Characteristics and Prognosis Analysis of Triple-negative Br.docVIP

Discussion on the Clinical Pathological Characteristics and Prognosis Analysis of Triple-negative Br 　　Abstract. Objective: The clinical characteristics of the cases with triple-negative breast cancer were studied, and also the prognosis of this cancer was comprehensively analyzed. Methods: The materials of 120 cases with triple-negative breast cancer, receiving a treatment in Hongqi Hospital from October 2011 to October 2012, were randomly selected; the clinical conditions of these cases were retrospectively analyzed; prognosis analysis was made to the characteristics of the cases with triple-negative breast cancer after a definite diagnosis. When these cases were definitely diagnosed, 100 cases were classified into 4 groups according to estrogen receptor, progesterone receptor, and human epidermal growth factor receptor, and also prognosis analysis was made to all of them. Results: the characteristics of the cases with triple-negative breast cancer were very complex; compared with other types of breast cancer, triple-negative breast cancer features high recurrence risk, long course of disease, and difficult treatment. Conclusion: The prognosis analysis of triple-negative breast cancer is helpful for guiding clinical treatment and reducing all kinds of risks caused by the recurrence of disease. 　　Key words: Estrogen Receptor; Progesterone Receptor; Human Epidermal Growth Factor; Pathological Mechanism; Prognosis Analysis 　　Introduction 　　In recent years, the incidence of breast cancer among Chinese women continues to rise by 5%-10% annually, making the normal healthy condition of Chinese women seriously affected. Along with the in-depth development of the studies on clinical cases, some new breast cancers have been discovered and triple-negative breast cancer (TNBC) can be commonly seen among them. TNBC is a complex breast cancer clinically, in which estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) were n